88.5 F
San Fernando
Saturday, Jun 6, 2026
Home Blog

Guitar Center Closes HQ Sale-Leaseback

Site: Guitar Center sold its Westlake Village headquarters to a group of investors. (Photo c/o Arise)

Coming off a major debt restructuring, musical instrument retailer Guitar Center has sold its Westlake Village headquarters to a cohort of investment firms for $19.3 million.

Beverly Hills-based Arise Investments, Oak Park Investments in Westwood and Nebraska’s Nelnet Real Estate Ventures acquired the 98,086-square-foot warehouse property in an off-market sale-leaseback deal.

The sale, announced Tuesday, gave Guitar Center access to the asset’s full equity and a path to consolidating its headquarters, said Danny Soroudi, principal at Arise. 

“It was part of their overall debt restructuring to give them a lot more flexibility and liquidity, and they just didn’t want to own their own real estate anymore,” Soroudi said.

For at least the next three years, Guitar Center will stay on as the sole tenant of the two buildings it has occupied at 5775-5785 Lindero Canyon Road since the early 2010s. The company, which did not respond to the Business Journal’s request for comment on the transaction, also leases office space in a third building in the complex managed by a separate owner.

Strategic initiatives aim to ease debt load

One of the last music retailers left standing, Guitar Center buckled under the weight of the e-commerce boom and pandemic-time disruptions, filing for Chapter 11 bankruptcy in 2020. 

Last August, the company secured a three-year extension to its $1-billion debt, much of which came from a leveraged buyout by private equity firm Bain Capital in 2007. It now has until 2029 to execute on its revamped business plan, including the anticipated launch of an in-house guitar brand and refined product assortments, and pay up. 

Guitar Center Chief Executive Gabe Dalporto told the Business Journal last fall that a return to serving the “serious musician” with an inventive, engaging retail experience was key. Last summer, the retailer’s 300 stores rolled out Rig Adviser, an artificial intelligence-powered shopping assistant that makes gear recommendations.

Gabe Dalporto

“Frankly, the company was struggling when I took over as CEO. We were about to deliver our ninth consecutive quarter of negative growth,” said Dalporto, who launched into turnaround efforts when he took the helm in 2023. “If I really boil it down to the simplest terms, the company had forgotten who its core customer was.”

Though the debt exchange and fresh initiatives helped upgrade Guitar Center’s S&P Global rating to ‘CCC+’ from ‘SD,’ or selective default, in August, the credit rating agency still passed concern on the company’s outlook. 

“Although the transaction provides the company with time to execute its strategic initiatives, Guitar Center’s capital structure remains unsustainable given its high leverage and free operating cash flow deficits amid a difficult consumer environment,” S&P wrote in its report.

A deal worth chasing

The investor group that bought Guitar Center’s corporate campus at $200 per square foot plans to hold the asset for five to 10 years, Arise’s Soroudi said. Once the company wants to move out, the firms will either move a new tenant in or sell to an owner-user.

The deal, financed by California Bank and Trust, is Arise’s first in the San Fernando Valley. The property’s location in Westlake Village was attractive, given low vacancy rates and growing demand for flexible industrial space to sustain the region’s biotech and pharmaceutical industries, Soroudi said. 

“Guitar Center right now is really utilizing this as more of an office building for the corporate offices. It’s really, to us, more of an industrial or flex research and development lab,” he said. 

Strong fundamentals and the opportunity to present a creative solution that fits investors’ long-term goals made the property – Soroudi’s third sale-leaseback alongside two industrial facilities in Arizona – a valuable get. 

“We had been chasing this site for over a year,” he said.

Tutor Perini Snags Coast Guard Deal

Leader: Gary Smalley is chief executive of Tutor Perini Corp. (Photo by David Sprague)

Sylmar-based Tutor Perini Corp. has won an $81.8 million federal contract to design and build family housing at U.S. Coast Guard Base Kodiak in Alaska, the company announced on May 27.

The contract, awarded to Tutor Perini’s subsidiary Perini Management Services Inc. in Framingham, Mass., covers the development of 30 family housing units – 20 three-bedroom and 10 four-bedroom – across 15 duplex configurations at the Nemetz Park Site. It also includes demolition, utilities, roads and sidewalks, and the replacement of the base’s 653,800-gallon Aviation Hill water storage tank and associated tie-ins to support fire protection and domestic water services.

Work is slated to begin immediately, with “substantial completion” by November 2028. The contract value be added to the company’s second-quarter backlog.

A strong run

The award adds to Tutor Perini’s strong run. The company posted first-quarter 2026 revenue of $1.4 billion, up 11% year-over-year, and recorded its fourth consecutive year of record operating cash flow in 2025, generating $748.1 million – up 49% year-over-year. The company has said it expects adjusted earnings per share for 2027 to be significantly above the upper end of its 2026 guidance range, citing backlog visibility.

Founded originally in 1894, Tutor Perini operates across civil, building and specialty construction. Perini Management Services specializes in federal construction, including military and government housing.

Flashfood Expands to All Gelson’s

Gelson's Market in Sherman Oaks. (Photo by David Sprague)

Having stepped into Los Angeles’ food scene in an initial collaboration with Encino-based Gelson’s Markets last October, Flashfood Inc. is now bringing its $9 grocery boxes to all Gelson’s locations.

The Toronto-based mobile platform connects shoppers to discounted surplus groceries from more than 2,000 partnering stores across North America. Gelson’s was its first footprint in L.A. County, which started offering discount grocery boxes in six locations, including Silver Lake and West Hollywood.

The boxes were popular and often sold out, said Jordan Schenck, chief executive of Flashfood. Shoppers have snagged more than 1,000 produce boxes since November, weighing around 10,000 pounds.

“L.A. was on our radar as this perfect market for Flashfood, and it’s proved nothing but that so far,” Schenck said. “With L.A. consumers, you get the health component – so much of fresh food is just healthy, good food – and you also have a greater awareness of sustainability.”

The boxes would come to 26 stores across Southern California. Gelson’s operates in Orange County, Ventura County and San Diego County beyond L.A.

“We are encouraged by how quickly customers have responded to and embraced this program,” said Rick Williams, chief merchandising and marketing officer for Gelson’s, in a statement. “And with California’s peak produce season upon us, the timing is right to expand Flashfood to all of our locations.”

Food insecurity and sustainability in L.A.

The initial collaboration came at a time when Supplemental Nutrition Assistance Program (SNAP) paused due to a federal government shutdown. Flashfood saw a spike in engagement on its platform, and the momentum continued.

On the other hand, food insecurity persists in the region. According to a December study conducted by the University of Southern California’s Dornsife College of Letters, Arts and Sciences, though food insecurity among low-income households declined from 41% to 35% compared to 2024, rates are still higher than pre-pandemic levels. Higher-income Angelenos also increasingly face food insecurity.

The new expansion into all Gelson’s locations marks the potential for more Southern California collaborations, according to Schenck.

“You’ll start to see a few more locations across Southern California carry us, with unique assortments that go beyond produce to meat and dairy,” Schenck said. “Gelson’s effectively opened up L.A. for us. Now we’re opening up Southern California.”

Firms Sell Two Valley-Area Apartment Complexes

Housing: Universe Holdings Development buys Park Encino in Encino for $28 million. (Photo c/o Marcus & Millichap)

Two large multifamily assets in San Fernando Valley were sold recently.

In one sale, Universe Holdings Development purchased Park Encino, a 52-unit apartment complex in Encino, for $28 million.

The Marcus & Millichap Institutional Property Advisors team of Kevin Green, Joseph Grabiec and Gregory Harris represented the unnamed seller and procured the buyer for the $538,462 per unit sale. IPA’s Brian Eisendrath, Cameron Chalfant and Patrick Barker arranged the acquisition financing for the asset.

Green, IPA’s executive managing director of investments, noted in a statement that the size of the sale was unique for the area.

“Despite favorable demographics, strong submarket fundamentals and increased demand for housing, no institutional-sized multifamily projects of 50-plus units have been delivered in Encino since 2016,” Green said. “This transaction represents the first core-plus, 50-plus unit multifamily sale in Encino since 2017.”

Grabiec added that multifamily occupancy in the area is more than 97%, while median single-family home values in the neighborhood rose by more than 75% in the last 10 years.

Built in 2014, the Park Encino is within walking distance of Ventura Boulevard and near a number of major employment centers. It has a central courtyard, clubhouse, fitness center, patio and barbecue area.

Van Nuys property

Meanwhile, a 390-unit property dubbed the San Regis in Van Nuys sold for $69 million in April, according to CoStar Group Inc. It’s the largest multifamily transaction by unit count to sell in Van Nuys since 2015, according to Marcus & Millichap. San Regis is made up of five buildings and two levels of underground parking, and it has a large swimming pool, three pickleball courts and a fitness center.

Nuveen Real Estate sold the property to an unnamed buyer. Green, Harris and Grabiec represented the seller in the transaction.

“As the boundaries and strong demographics of Sherman Oaks and Encino continue to push north, Van Nuys has benefitted from strong demand for renovated apartment homes in the San Fernando Valley,” Green said. “Because of nearly $17 million invested in capital improvements since 2020, this 1960s-vintage asset’s effective age is closer to 2000, which helped drive interest and activity.”

Grabiec added that “we continue to provide investors with multiple opportunities to add value, including converting market-rate apartments to affordable housing.”

The property is near the Van Nuys G Line Metro station and the Van Nuys Metrolink train station.

Potential issues ahead

According to Marcus & Millichap’s multifamily investment forecast, there are some “near-term hurdles” facing Los Angeles.

One hurdle is strict immigration policies. The area is home to the fourth-largest immigration population, according to the report.

The turmoil in the entertainment industry – leading to a decline in jobs – may also be impacting the renter pool. In the last three years, the brokerage found that the number of Angelenos in the motion picture industry declined by at least 40,000.

One bright side for investors, however, is that the market is expected to have very little supply pressure this year. Only 6,200 units are coming online, which is the lowest number since 2015.

A number of investors are interested in the area, with L.A. being the major market for the most transactions last year. Assets below $5 million made up the bulk of those sales.

The San Fernando Valley is expected to represent a number of trades in 2026.

Amgen Drug Reviewed Amid Deaths

Amgen's headquarters in Thousand Oaks. (Photo c/o Amgen)

Sales of the problematic Amgen Inc. drug Tavneos resumed late last week in Japan with a new warning label after several patient deaths potentially linked to the drug.

The drug’s future in the United States is still uncertain amid renewed regulatory scrutiny following revelations of alleged data manipulation in clinical trials for the drug several years ago.

Tavneos, which also goes by the generic name avacopan, was developed by San Carlos-based ChemoCentryx Inc. to treat several rare autoimmune diseases or conditions that cause inflammation in small blood vessels. That inflammation can sometimes be fatal. Tavneos is often prescribed in combination with other drugs.

Thousand Oaks-based Amgen bought ChemoCentryx in late 2022, nearly a year after the drug had been approved and had gone on the market. In its 2025 annual report, Amgen listed Tavneos sales at $459 million.

Patient deaths in Japan

Nagano, Japan-based Kissei Pharmacutical, which holds the license to sell Tavneos in that country, reported on May 15 that 20 people who were taking the drug had died from injuries to the liver. Kissei Pharmaceutical said that while a direct link to Tavneos had not been established in all the deaths, it was nonetheless recommending that all clinicians in Japan stop writing new prescriptions for it immediately.

Amgen issued a statement the same day noting that the 20 deaths were out of a total of roughly 8,500 patients taking the drug in Japan. The company also noted that there had been no fatalities in the U.S. from liver injuries among the more than 8,000 patients in this country who have taken the drug.

After meeting with Japan’s Ministry of Health last week, Kissei Pharmaceutical announced last week it was sending an emergency warning to all clinicians in Japan that use of the drug could lead to severe liver dysfunction, including vanishing of bile ducts that drain waste products from the liver. The same warning label would be placed on all future packaging. With those conditions in place, Kissei said health practitioners could resume prescribing the drug.

The Japanese Ministry of Health simultaneously advised that all doctors and other health practitioners carefully monitor any patients taking Tavneos. The agency recommended that patients already taking Tavneos shouldn’t on their own stop taking it but should instead consult with their physicians about the best course forward.

Amgen in its statement said similar warnings have long been on Tavneos drug packaging within the United States.

Trouble in the U.S.

Meanwhile, the future status of the drug in the U.S. is uncertain.

On April 27, the Center for Drug Evaluation and Research, a division of the U.S. Food and Drug Administration, sent a letter addressed to Nicole Cheung, Amgen’s manager of global regulatory affairs, stating that the division is proposing to withdraw approval of the new drug application for Tavneos that the FDA had granted in 2021.

In its letter, the Center for Drug Evaluation and Research detailed allegations that had recently come to light that endpoint results for a Phase 3 clinical trial conducted in 2019 for ChemoCentryx’ drug were manipulated to make the drug appear effective “when the original analysis did not support that conclusion.”

The letter maintains that if the original results had been submitted instead of the manipulated results, the drug would not have been determined to be effective.

The letter also noted that liver toxicity was identified as a key safety risk in the original material reviewed by the FDA back in 2021.

Amgen has two options in response to the approval withdrawal notice: On its own pull the drug from the market or request a hearing with the Center for Drug Evaluation and Research. If Amgen chooses the hearing route, it has until June 1 to submit its hearing request and until June 29 to submit all data in support of that request.

In its May 15 statement, Amgen indicated it “continues to engage with the FDA regarding Tavneos.”

Meanwhile, Tavneos is also under review by the European Medicines Agency, the main drug regulating authority for the European Union with its 27 member nations.

Wage Hikes to Be Delayed

Travel: Hotel workers’ pay to be $30 an hour in 2030. (Photo by David Sprague)

Last week, L.A. City Council reached a deal to extend the timetable for boosting wages for hotel and private-sector airport workers under the Olympic tourism wage ordinance, in exchange for business groups dropping their measure to repeal the city’s gross receipts tax.

The council approved a revised plan in an initial 11-4 vote, delaying the target wage level of $30 an hour by 18 months to Jan. 1, 2030. Because the decision wasn’t unanimous, the council will have to vote again this week on the ordinance.

Travel industry and business groups had qualified a ballot measure for November to repeal the city’s gross receipts tax. In exchange for the wage delay, these groups agreed to drop that measure.

“This agreement ensures workers are paid fairly and that businesses that create jobs can continue serving L.A. and hiring Angelenos,” said L.A. Mayor Karen Bass said following the council’s initial vote.

Bass had previously met with the business and labor groups to begin brokering the deal which the city council is now voting on.

The gross receipts tax is expected to bring in roughly $890 million to city coffers for the 2026-27 fiscal year that starts July 1. Out of a general fund budget of $8.2 billion, it is the third largest revenue source behind property taxes and department receipts.

Original wage plan

The tourism wage ordinance was originally passed in May of last year after a years-long campaign by the Unite HERE Local 11 union of hotel and restaurant workers. That ordinance increased the minimum wage paid to hotel and private sector airport workers to $30 an hour by 2028.

The American Hotel and Lodging Association, Chicago-based United Airlines and Atlanta-based Delta Air Lines immediately attempted to place a referendum on the ballot so that they could campaign to overturn that ordinance. 

However, amid controversy over signature-gathering practices, that effort failed to garner enough valid signatures, and the first wage hike took effect.

The lodging association and airlines then pivoted to the repeal the gross receipts tax, joining the Valley Industry and Commerce Association and other business groups that had long been pushing for the elimination of the tax. In March, the business interests were successful in garnering enough signatures to place the measure on the November ballot.

Faced with the prospect of an $890 million hole being blown in their budget, city officials then turned to negotiations to convince the business groups to withdraw their repeal measure. The outlines of a deal were first reported two weeks ago.

‘Important step forward’

The council’s initial vote was welcomed by the Central City Association, one of the principal negotiators in the deal.

“Today is an important step forward for Los Angeles’ tourism and hospitality industries, and for the workers and businesses that create them,” the downtown business group said in a statement. “We reached an agreement that raises wages, expands healthcare benefits – but also recognizes the economic realities these industries are facing.”

The statement went on to say that the initial ordinance the council approved last year lacked business input.

“We should not repeat that approach,” the statement said.

But Unite HERE Local 11 blasted the deal.

“The hotel and airline industry’s successful shakedown sends a dangerous message: Any time workers win meaningful improvements, powerful corporations can threaten the city’s finances and strong-arm elected officials into taking back wages and healthcare that workers fought to win,” the union’s statement said.

Bass Unveils City’s First Capital Fund

Press: Karen Bass discusses the city's new capital program. (Photo c/o Mayor Bass Communications Office)

Most other major cities have capital infrastructure budgets, but for its 175 years as a U.S. city, Los Angeles hasn’t had one – until now.

On May 4, Los Angeles Mayor Karen Bass unveiled the city’s first capital infrastructure program that streamlines the budgeting and delivery of infrastructure projects. It lays out a comprehensive roadmap for the city to improve the way it maintains and builds new infrastructure.

“With my capital infrastructure program, we are forging a new path together to better design, maintain and deliver – on time and budget – the infrastructure that Angelenos deserve,” Bass said at a news conference. “We will finally responsibly plan for long-term improvements to our streets, sidewalks, parks and every piece of infrastructure across Los Angeles.”

Preparing for the Games

The principal focus of this first capital infrastructure budget is the 2028 Summer Olympic and Paralympic Games. The budget includes 29 capital projects tied to the Olympic Games, including a whole series of road and access improvements around individual venue sites, such as Exposition Park, the Sepulveda Dam Recreation Area in the San Fernando Valley and the Athletes’ Village at UCLA.

Bass noted that 16 of the Olympics-related projects are funded in the upcoming fiscal 2026-2027 budget that takes effect on July 1.

The capital infrastructure program does not apply to the city’s three proprietary departments that generate their own revenues: the Department of Water and Power, Los Angeles World Airports and the Port of Los Angeles. Each have their own capital improvement budgets.

Atara Bounces Back with FDA

Atara Biotherapeutics' headquarters in Thousand Oaks.

The share price of Thousand Oaks-based immunotherapy company Atara Biotherapeutics nearly doubled on May 7 after a welcome dose of positive news.

The company reported that the U.S. Food and Drug Administration has laid out a path for resubmission of Atara’s cell therapy drug candidate that the agency had twice before rejected.

Shareholder jubilation was immediate. Within hours, Atara’s stock had nearly doubled to $10 a share. The price closed on May 7 at $9.93 – up 93% – with a record volume of 77 million shares. The stock slipped a bit in the following days though rebounded on May 13, a day after the company’s earnings release, closing at $10.48. The price still remains below the $14 to $18 range the stock was trading before news of the FDA’s second rejection hit in early January.

FDA rejections

Atara’s drug, called tabelecleucel (tab-cel for short), targets a rare and often fatal blood cancer that can occur after organ or stem cell transplants. Atara developed the drug in partnership with Paris-based pharma giant Pierre Fabre Laboratories. The latter company has taken the drug through the FDA regulatory process. The drug had already been approved in 2022 for sale in the European Union nations under the brand name Ebvallo.

In January of last year, the FDA rejected the drug for the first time, citing deficiencies in the manufacturing process, a common issue that arises in initial FDA reviews of drug applications. After meeting with the FDA to map out a corrective course of action, Pierre Fabre resubmitted the drug last summer to the FDA, fully expecting approval.

But in early January, the FDA shocked both companies by rejecting the drug a second time. The issue this time was more substantial: the failure to include “double-arm” clinical trial results in the application. A double-arm clinical trial is considered the gold standard. It involves one group of participants that receive the drug and another control group that receives either a placebo or the existing standard therapy.

In an interview with the Business Journal, Atara Chief Executive Cokey Nguyen said that they didn’t consider it ethical to deny some clinical trial participants the potentially life-saving drug. Instead, the companies used pre-determined baseline standards in so-called “single-arm” clinical trials.

Cokey Nguyen

News of this second denial was devastating: Atara’s share price plunged by more than two-thirds over two days as many shareholders concluded this denial was the FDA’s final word on the application. The denial was also taken as a sign that the FDA under the second administration of President Donald Trump was being far more rigorous in its reviews of new drug applications.

Hopeful meeting with FDA

Pierre Fabre sought and was granted another meeting earlier this month with the FDA to try to map out a way forward for approval. According to an announcement released on May 7 from Atara Biotherapeutics, the FDA agreed in the meeting to allow the usage of the single-arm clinical trial method. In exchange, Pierre Fabre agreed to submit additional data with a longer period of patient follow-up.

“We appreciate the FDA’s continued engagement with PFP and Atara, and we believe the Type A Meeting provided helpful alignment on the regulatory framework to resubmit,” Nguyen said in the announcement.

No timeline was given for resubmission of this expanded clinical trial data to the FDA. But Nguyen said an update would be issued in the third quarter.

One year cash runway

Last week, Atara released its quarterly earnings statement. The company reported $516,000 in revenue during the first quarter, down sharply from $98.2 million for the same quarter last year. The company noted that last year’s revenue figure was impacted by a one-time acceleration of sales as it transferred tabelecleucel manufacturing to Pierre Fabre.

Atara reported a net loss of $4.15 million for the first quarter as opposed to a gain of $38 million for the same quarter last year – also impacted by the one-time transfer. Atara reported that it expects its cash runway to last until the middle of next year, thanks to $4.8 million in proceeds from recent share offerings and extensive cutbacks. The company has shed more than 95% of its staff over the last five years.

Thousand Oaks Financial Adviser Joins National RIA

Vicki Arndt

A national registered financial advisory firm on an acquisition spree has snapped up Thousand Oaks-based Eagleson Arndt Financial Advisors.

In the last year, Mercer Advisors brought 18 firms under its wing, including two in the Los Angeles area, where it manages $3.2 billion in client assets of its $98 billion total.

Eagleson Arndt, composed of veteran adviser Vicki Arndt and client manager Kathryn Freid overseeing $100 million in assets, is the Denver-based RIA’s latest add-on.

Arndt is a “powerhouse,” said Martine Lellis, executive managing partner for M&A partner development at Mercer.

“She’s an amazing adviser … serving as a fiduciary, putting her clients first and leading with planning,” Lellis said. “(She is) a very natural fit for continuing to build out that team.”

Martine Lellis

Mercer positions itself as an integrator as opposed to an aggregator, despite its aggressive inorganic growth strategy, encouraging partner firms to operate independently with added scale and support, Lellis said.

“We don’t want to diminish what (Arndt) was capable of doing on her own,” she said. “It’s just going to help her create a more integrated process of delivery for wide-ranging advice that will incorporate areas like tax and estate planning and investments in other areas that her clients may need.”

‘Opportunity’ in L.A. markets

In a competitive, consolidating wealth management sector, smaller firms balance compliance, technological advancements and a patchwork of external solutions providers. Lellis said many firms that approach Mercer want to lift their operational burden.

“We have a lot of sellers who come to us because they are just in a state of wearing a lot of hats,” she said. “It’s taking them away from doing what a lot of them decided was going to be their life’s work.”

The deal builds on Mercer’s growing presence in and around L.A., where it runs six offices – including in Woodland Hills, Encino and Century City – staffed by 16 advisers and their teams. In October, the firm acquired Encino-based wealth management, tax and business advisory firm Singer Burke and its $1.2 billion in managed assets.

“Southern California is very attractive,” Lellis said. “There’s opportunity in the L.A. and Orange County markets, so we want to continue to try to activate those and bring our services to those clientele.”

Avem Takes Stake in Valley Aircraft Parts Maker

A Sun Valley-based precision manufacturing firm with deep ties to the aerospace and defense industry has scored local private equity backing.

Precision Aircraft Machining Co. Inc., or Pamco, has been acquired by Avem Partners, a private equity firm based in Manhattan Beach, with additional capital support from True West Capital Partners, prominent family offices and high-net-worth investors. Avem principals and several aerospace industry executives also put up significant investment. Financial terms were not disclosed.

The deal will advance Pamco’s scaled platform supplying source-controlled fluid conveyance fittings for some of the biggest names in aerospace and defense, including SpaceX, Boeing and Northrop Grumman.

“Joining the Avem platform represents an exciting next chapter for Pamco,” said Pamco President Kim Pisano in a news release. “The partnership with Avem will allow us to build on our strong foundation and continue to expand our capabilities and customer support.”

Avem will step in to help Pamco expand production, enhance efficiency and pursue both organic and inorganic growth opportunities. 

Nearly a decade of investments

Pamco, founded in 1980, is one of Avem’s four current portfolio companies. The private equity firm has invested in North American lower-middle-market aerospace and defense companies since 2017. 

“Pamco is a strong addition to our aerospace and defense manufacturing platform, with deep technical capabilities, a long history of quality performance, and a highly skilled team,” said Brian Leibl, partner at Avem, in the release.

The firm’s push to expand its footprint in the aerospace and defense sectors took a “pivotal step” last April, when the company announced it acquired Valencia-based FMI Aerostructure Inc. out of bankruptcy. Like Pamco, FMI has a history of supplying parts to major clients like Lockheed Martin Corp., Boeing Co., Northrop Grumman Corp. and Blue Origin.

Among Avem’s seven realized investments is Aero Pacific Corp., a Garden Grove-based aerospace supplier that provides assemblies and aerostructures to advanced aircrafts, including the Boeing 787 Dreamliner. The company sold to contract manufacturer ARCH Global Precision in 2019 and now operates as part of the Align Precision network.